ANGLE (ANPCF) Risk Assessment

View and export this data going back to 2014. Start your Free Trial

What is ANGLE Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of ANGLE is: No Data: Cannot be evaluated.

Competitive Comparison of ANGLE's Risk Assessment

For the Diagnostics & Research subindustry, ANGLE's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ANGLE's Risk Assessment Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ANGLE's Risk Assessment distribution charts can be found below:

* The bar in red indicates where ANGLE's Risk Assessment falls into.

ANGLE (OTCPK:ANPCF) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

ANGLE Risk Assessment Related Terms

Thank you for viewing the detailed overview of ANGLE's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

ANGLE (ANPCF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » ANGLE PLC (OTCPK:ANPCF) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

ANPCY:USA AGL:UK DWV:Germany

Address

10 Nugent Road, The Surrey Research Park, Surrey, Guildford, GBR, GU2 7AF

Website

https://www.angleplc.com

ANGLE PLC is active in the healthcare sector in the United Kingdom. It is a medical diagnostic company specializing in the development of pioneering products in cancer diagnostics. Its patented Parsortix technology can potentially treat and diagnose various forms of cancer. The Parsortix system can capture and harvest CTCs from patient blood. Its geographical segments include Europe and North America, of which majority of its revenue is generated from Europe.

ANGLE (ANPCF) Headlines

From GuruFocus

Angle PLC Announces Holding(s) in Company - (2)

By ACCESSWIRE ACCESSWIRE • 07-08-2020

Angle PLC Announces Exercise of Options and Total Voting Rights

By ACCESSWIRE ACCESSWIRE • 04-30-2021

Angle PLC Announces Harvesting CTCs from Brain Metastasis Patients

By ACCESSWIRE ACCESSWIRE • 07-09-2021

Angle PLC Announces Parsortix-Harvested CTCs Uncover Novel Biomarker

By ACCESSWIRE ACCESSWIRE • 02-18-2021

Angle PLC Announces Holding(s) in Company - (1)

By ACCESSWIRE ACCESSWIRE • 07-08-2020

Angle PLC Announces AACR 2019

By ACCESSWIRE AccessWire • 04-12-2019